poisar

Stocks · News reference

8-K filing — Dare Bioscience, Inc. (DARE)

SEC EDGARSEC EDGAR

Filed: 2026-09-11 AccNo: 0001401914-26-000050 Size: 153 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure

    The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"